Therakind

Dridose

Dridose

DriDose® is a Dry Powder Intranasal Device which can be utilised for nasal delivery of vaccines, peptides, proteins and small molecules (avoids IV route and first pass metabolism of oral route).

DriDose® - dry powder intranasal device

• Simple to operate - can be used one-handed
• Dose immediately available – no reconstitution
• Drug delivered as a stable, fine, dry powder by positive air pressure, providing accurate and consistent dose delivery
• Patient can be unconscious as inhalation not required
• Does not require an aerosol
• Refrigeration less likely to be required
• Simple construction – easy and inexpensive to manufacture in single and multi-dose formats
• Suitable for automated filling and assembly
• Patent protected

DriDose® - a suitable device for intranasal vaccines

• Nasal vaccines induce humoral, cellular, and mucosal immunity. This route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body1
• Nasal vaccines offer a simplified and cost-effective mode of vaccination with enhanced patient compliance due to ease of administration without needles, avoiding issues associated with needlestick injuries and disposal2.
• Dry powder is more stable than nasal liquid, has less potential for bacterial growth and is thus less likely to require cold chain storage.
• Immunity within days instead of weeks (some studies have suggested a local immune response within 24-48 hours 3,4).